In the cerebrovascular amyloid Nos2<sup>-/-</sup> (CVN) mouse model of AD, administration of 120 μg of siRNA via the intracerebroventricular route produced reductions in APP expression, with mRNA levels remaining suppressed for 60 days in the ventral cortex. The gene discussed is APP; the disease is Alzheimer disease.